Top

Published in:

01-04-2016 | Commentary

A premature proposal for new liver cancer seromarkers

Authors: Liu-Cheng Wu, Wen-Feng Gong, Jian-Hong Zhong

Published in: Tumor Biology | Issue 4/2016

Excerpt

Optimal treatment of liver cancer depends on correctly determining whether tumors are primary hepatocellular carcinoma (HCC) or secondary carcinoma that metastasized from an extrahepatic source. Nearly all cancers that originate outside the liver can metastasize to that organ, raising the risk of misdiagnosis and suboptimal treatment. Indeed, the incidence of HCC in China is similar to that of metastatic liver carcinoma. While pathology provides the best method for differentiating primary and secondary cancer, it is rarely used preoperatively to diagnose liver cancer. …

Colli A, Fraquelli M, Casazza G, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol. 2006;101(3):513–23.CrossRefPubMed

Chang TS, Wu YC, Tung SY, et al. Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis. Am J Gastroenterol. 2015;110(6):836–44. quiz 845.CrossRefPubMed

Siripongsakun S, Wei SH, Lin S, et al. Evaluation of alpha-fetoprotein in detecting hepatocellular carcinoma recurrence after radiofrequency ablation. J Gastroenterol Hepatol. 2014;29(1):157–64.CrossRefPubMed

Kudo A, Matsumura S, Ban D, et al. Does the preoperative alpha-fetoprotein predict the recurrence and mortality after hepatectomy for hepatocellular carcinoma without macrovascular invasion in patients with normal liver function? Hepatol Res. 2014;44(14):E437–46.CrossRefPubMed

Abdel-Hamid NM, Abouzied MM, Nazmy MH, Fawzy MA, Gerges AS. A suggested guiding panel of seromarkers for efficient discrimination between primary and secondary human hepatocarcinoma. Tumour Biol. 2015: [Epub ahead of print].

Zhong JH, Ke Y, Gong WF, et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg. 2014;260(2):329–40.CrossRefPubMed

Zhong JH, Wu FX, Li H. Hepatic resection associated with good survival for selected patients with multinodular hepatocellular carcinoma. Tumour Biol. 2014;35(9):8355–8.CrossRefPubMed

Zhong JH, You XM, Lu SD, et al. Historical comparison of overall survival after hepatic resection for patients with large and/or multinodular hepatocellular carcinoma. Med (Baltimore). 2015;94(35), e1426.CrossRef

Trevisani F, D’Intino PE, Morselli-Labate AM, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001;34(4):570–5.CrossRefPubMed

10.

Omata M, Lesmana LA, Tateishi R, et al. Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4(2):439–74.CrossRefPubMedPubMedCentral

11.

Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis. 2011;29(3):339–64.CrossRefPubMed

12.

Li C, Zhang Z, Zhang P, Liu J. Diagnostic accuracy of des-gamma-carboxy prothrombin versus alpha-fetoprotein for hepatocellular carcinoma: a systematic review. Hepatol Res. 2014;44(10):E11–25.CrossRefPubMed

13.

Dai M, Chen X, Liu X, Peng Z, Meng J, Dai S. Diagnostic value of the combination of golgi protein 73 and alpha-fetoprotein in hepatocellular carcinoma: a meta-analysis. PLoS One. 2015;10(10):e0140067.CrossRefPubMedPubMedCentral

14.

Zhou Y, Yin X, Ying J, Zhang B. Golgi protein 73 versus alpha-fetoprotein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. BMC Cancer. 2012;12:17.CrossRefPubMedPubMedCentral

15.

Jia Z, Wang L, Liu C, Yu Z, Chai L, Zhao M. Evaluation of alpha-fetoprotein-L3 and Golgi protein 73 detection in diagnosis of hepatocellular carcinoma. Contemp Oncol (Pozn). 2014;18(3):192–6.

16.

Zhao Y, Wang M, Cui C, et al. Significance of combined tests of serum golgi glycoprotein 73 and other biomarkers in diagnosis of small primary hepatocellular carcinoma. Cancer Biomark. 2015;15(5):677–83.CrossRefPubMed

Title: A premature proposal for new liver cancer seromarkers
Authors: Liu-Cheng Wu
Wen-Feng Gong
Jian-Hong Zhong
Publication date: 01-04-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 4/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-4801-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

ACC 2024 Congress

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2016

Enhanced SLC34A2 in breast cancer stem cell-like cells induces chemotherapeutic resistance to doxorubicin via SLC34A2-Bmi1-ABCC5 signaling

Mitotic arrest deficient-like 1 is correlated with poor prognosis in small-cell lung cancer after surgical resection

Comparison of five models for end-stage liver disease in predicting the survival rate of patients with advanced hepatocellular carcinoma

Inhibition of cyclin D1 enhances sensitivity to radiotherapy and reverses epithelial to mesenchymal transition for esophageal cancer cells

miRNA profiling in serum and tissue samples to assess noninvasive biomarkers for NSCLC clinical outcome

RETRACTED ARTICLE: Overexpression of OCT4 contributes to progression of hepatocellular carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer